Date: 2013-07-30
Type of information: Collaboration agreement
Compound: midkine (heparin-binding growth factor)
Company: Abcodia (UK) Cellmid (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease: colorectal cancer
Details: Abcodia, a UK biomarker validation company with a focus on early detection of cancer, has entered into a collaboration agreement with Cellmid Ltd, for the testing of midkine (MK) in a collection of longitudinal serum samples using Cellmid’s MK-ELISA. The initial objective of the collaboration is to validate midkine as a useful marker for the screening and early diagnosis of colorectal cancer. Serum samples will be provided by Abcodia and testing will be carried out by Cellmid. The collaboration focuses on the assessment of midkine in pre-diagnosis serum samples. Abcodia has exclusive access to a unique biobank of 5,000,000 serum samples collected through the UK Collaborative Trial for Ovarian Cancer Screening. The biobank was derived from 200,000 initially healthy volunteers. Since first recruitment, more than 27,000 individuals have been diagnosed with cancer. A subset of 50,000 individuals within the 200,000 cohort have provided samples annually, making this a unique longitudinal resource for testing midkine levels early, even before symptoms appear. The collaboration agreement allows for the testing of multiple cancer indications, but initially targeting the early detection and screening of colorectal cancer.
Financial terms:
Latest news:
